Breaking News

Northwest Biotherapeutics Adds Production Capacity at UK Facility

Dendritic cell vaccine production capacity for personalized immune therapies increases from about 4 - 6 patients per month to about 40 - 45 patients per month.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, completed development of the initial production capacity of its Sawston, UK advanced manufacturing facility. The company currently anticipates that the certification application will be submitted to the UK MHRA within the next six to eight weeks. To date, the company’s production of dendritic cell vaccine products in the UK has been taking place in a GMP (clean room...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters